Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.

Kiessling R, Mao Y, Pico de Coaña Y

Clin. Cancer Res. 20 (6) 1401-1403 [2014-03-15; online 2014-02-13]

Disseminated malignant melanoma has a poor prognosis. Immunotherapy based on cytokines or checkpoint inhibitors has a protracted beneficial effect in a select group of patients. Understanding the mechanisms that inhibit tumor-specific T cells will help the development of biomarkers to formulate therapy for this disease. Clin Cancer Res; 20(6); 1401-3. ©2014 AACR.

SciLifeLab Fellow

Yumeng Mao

PubMed 24526737

DOI 10.1158/1078-0432.CCR-13-3388

Crossref 10.1158/1078-0432.CCR-13-3388

pii: 1078-0432.CCR-13-3388

Publications 9.5.0